ClinicalTrials.gg

Program

fingolimod

Also written as “Fingolimod”, “FTY720” and “Fingolimod 0.5 mg”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · Renal Insufficiency · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · Multiple Sclerosis, Chronic Progressive, led by 4 companies.

Furthest: phase 4, since Sep 7, 201053 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis502 open or runningphase 4since Sep 7, 2010Dec 7, 2004none ahead
Alembic Pharmaceuticals10 open or runningphase 1since Nov 23, 2015Nov 23, 2015none ahead
Asofarma S.A.I. y C.10 open or runningphase 1since Nov 27, 2018Nov 27, 2018none ahead
Genuine Research Center, Egypt10 open or runningphase 1since Dec 2, 2020Dec 2, 2020none ahead

Also a collaborator on its studies: Hikma Pharmaceuticals, zenith-technology-corporation-limited and Tanabe Pharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Dec 7, 2004.

  1. Aug 13, 2012Phase 4 study in Multiple SclerosisNovartis · NCT01705236 · 87 enrolled · Germany, Switzerland
  2. Dec 21, 2012Phase 2 study in Optic NeuritisNovartis · NCT01757691 · 2 enrolled · United States, Spain
  3. Feb 12, 2013Phase 2 study in UveitisNovartis · NCT01791192
  4. May 8, 2013Phase 3 study in Multiple SclerosisNovartis · NCT01892722 · 240 enrolled · United States, Australia, Austria and more
  5. Sep 9, 2013Phase 3 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT01941004
  6. Sep 2, 2014Phase 4 study in Multiple SclerosisNovartis · NCT02232061 · 6 enrolled · Belgium, Germany, Italy
  7. Feb 4, 2015Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT02373098 · 126 enrolled · Turkey (Türkiye)
  8. Nov 23, 2015Alembic Pharmaceuticals's first study: phase 1 study in BioequivalenceNew to Alembic PharmaceuticalsAlembic Pharmaceuticals · NCT05145621 · 26 enrolled · Canada
  9. Mar 21, 2016Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNovartis · NCT02720107 · 133 enrolled · Germany
  10. Aug 18, 2017Phase 4 study in Multiple SclerosisNovartis · NCT03257358 · 382 enrolled · United States
  11. Nov 27, 2018Asofarma S.A.I. y C.'s first study: phase 1 study in Healthy VolunteersNew to Asofarma S.A.I. y C.Asofarma S.A.I. y C. · NCT03757338 · 33 enrolled · New Zealand
  12. Jul 17, 2020Phase 4 study in Multiple SclerosisNovartis · NCT04480853 · 14 enrolled · Taiwan
  13. Dec 2, 2020Genuine Research Center, Egypt's first study: phase 1 study in HealthyNew to Genuine Research Center, EgyptGenuine Research Center, Egypt · NCT04657744 · 34 enrolled · Egypt
  14. Dec 8, 2020Phase 4 study in Relapsing Multiple Sclerosis (RMS)Novartis · NCT04667949 · 98 enrolled · China

TargetBeta

“The hydrochloride salt form of fingolimod, an orally available derivate of myriocin and sphingosine-1-phosphate receptor 1 (S1PR1, S1P1) modulator, ”NCIt, by rule
“Sphingosine 1-phosphate receptor agonist; Sphingosine 1-phosphate receptor binding agent”ChEMBL 37, by rule

Studies

All 53 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT04667949Relapsing Multiple Sclerosis (RMS) · China4CompletedNovartisMar 25, 202598
NCT04657744Healthy · Egypt1CompletedGenuine Research Center, EgyptSep 28, 202034
NCT04480853Multiple Sclerosis · Taiwan4Active, not recruitingNovartisOct 15, 202614
NCT03757338Healthy Volunteers · New Zealand1CompletedAsofarma S.A.I. y C.Jan 26, 201633
NCT03257358Multiple Sclerosis · United States4CompletedNovartisMar 5, 2019382
NCT02720107Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedNovartisNov 14, 2016133
NCT05145621Bioequivalence · Canada1CompletedAlembic PharmaceuticalsJan 15, 201626
NCT02373098Multiple Sclerosis, Relapsing-Remitting · Turkey (Türkiye)4CompletedNovartisJan 18, 2017126
NCT02232061Multiple Sclerosis · Belgium, Germany, Italy4CompletedNovartisJan 24, 20206
NCT01941004Multiple Sclerosis, Relapsing-Remitting3WithdrawnNovartisMay 20170
NCT01892722Multiple Sclerosis · United States, Australia, Austria and more3Active, not recruitingNovartisJul 14, 2017240
NCT01791192Uveitis2WithdrawnNovartisOct 20140
NCT01757691Optic Neuritis · United States, Spain2TerminatedNovartisMay 20142
NCT01705236Multiple Sclerosis · Germany, Switzerland4CompletedNovartisFeb 18, 201987
NCT01633112Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Brazil and more3TerminatedNovartisApr 30, 20181,064
NCT01625182Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Belgium and more3CompletedNovartisSep 3, 2016106
NCT01623596Multiple Sclerosis, Relapsing-Remitting · United States, Puerto Rico4CompletedNovartisJul 13, 2015881
NCT01621269Multiple Sclerosis4WithdrawnNovartisJun 20140
NCT01585298Multiple Sclerosis · Germany4CompletedNovartisDec 12, 20166,998
NCT01578330Multiple Sclerosis · Turkey4CompletedNovartisApr 201542
NCT01534182Multiple Sclerosis, Relapsing-Remitting · Russian Federation4CompletedNovartisJun 2013298
NCT01498887Multiple Sclerosis, Relapsing-Remitting · Australia, Spain4CompletedNovartisDec 26, 2015347
NCT01497262Multiple Sclerosis · Argentina, Brazil, Colombia and more3CompletedNovartisApr 2014162
NCT01499667Multiple Sclerosis, Relapsing-Remitting · Australia, Austria, Czech Republic and more3TerminatedNovartisNov 2012142
NCT01420055Multiple Sclerosis, Relapsing-Remitting · France4CompletedNovartisJun 2013189
NCT01333501Multiple Sclerosis · Germany, Italy4CompletedNovartisSep 2015151
NCT01317004Multiple Sclerosis, Relapsing-Remitting · Italy4CompletedNovartisJun 201461
NCT01310166Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedNovartisJul 2012447
NCT01201356Multiple Sclerosis · United States, Argentina, Australia and more3CompletedNovartisOct 19, 20184,125
NCT01199861Relapsing Multiple Sclerosis · Belgium, Canada, Finland and more3CompletedNovartisMay 2011138
NCT01216072Relapsing Forms of Multiple Sclerosis · United States, Canada, Puerto Rico4CompletedNovartisAug 20121,053
NCT01127750Relapsing Multiple Sclerosis · Australia, Austria, Belgium and more3CompletedNovartisOct 20112,417
NCT00785083Asthma · United Kingdom2CompletedNovartisFeb 200936
NCT00731692Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more3TerminatedNovartisJun 22, 2015970
NCT00731523Renal Insufficiency · Russian Federation1CompletedNovartisAug 200818
NCT00670449Multiple Sclerosis · Japan2CompletedNovartisApr 2012143
NCT00662649Multiple Sclerosis · Australia, Belgium, Canada and more3CompletedNovartisJun 2011920
NCT00537082Multiple Sclerosis · Japan2CompletedNovartisFeb 2010171
NCT00416845Healthy · United States1CompletedNovartisMar 200739
NCT00355134Multiple Sclerosis · United States, Australia, Austria and more3CompletedNovartisJun 20111,083
NCT00340834Multiple Sclerosis · United States, Argentina, Australia and more3CompletedNovartisJul 20111,292
NCT00333138Multiple Sclerosis · Canada, Denmark, Finland and more2CompletedNovartisApr 2011281
NCT00289978Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Canada and more3CompletedNovartisJul 20091,272
NCT00239902Renal Transplantation2CompletedNovartisNov 2004396
NCT00239876Renal Transplantation3CompletedNovartisDec 2005140
NCT00239863Renal Transplantation3CompletedNovartisMay 2006684
NCT00239811Renal Transplantation3CompletedNovartisMay 2006684
NCT00239798Renal Transplantation2CompletedNovartisNov 2006255
NCT00239785Renal Transplantation3CompletedNovartisApr 2005684
NCT00099801Rejection, Psychology3CompletedNovartisMar 2006
NCT00099749Rejection, Psychology · United States3CompletedNovartisApr 2006255
NCT00099736Rejection, Psychology · United States3CompletedNovartisSep 19, 2005696
NCT00098735Rejection, Psychology3CompletedNovartisApr 2006140

How it is read

Names in the registry

  • “Fingolimod”, 22 entries
  • “FTY720”, 16 entries
  • “Fingolimod 0.5 mg”, 4 entries
  • “fingolimod”, 4 entries
  • “Fingolimod 1.25 mg”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.